This report was granted exemption from institutional review board approval. The authors report a case of endovascular recanalization and stent placement in the right hepatic vein (HV) by using a collateral loop-guided approach through a caudate-lobe patent accessory HV.
New Jersey) was advanced into the abdominal IVC. It was impossible to selectively cannulate the main HVs because of the confluence obstruction. The accessory HV draining the caudate lobe directly into the IVC was cannulated. A venous shunt between the accessory caudate lobe vein and the right HV was found. A roadmap image of this shunt was obtained (Fig 3) . A 180-cm-long, 0.035-inch nitinol guide wire (Terumo, Tokyo, Japan) was advanced through the shunt into the right HV. Venography at this time revealed a 4-cm obstruction of the right HV. It was possible to cross the obstructing clot and reach the IVC with the Terumo guide wire. The 6-F introducer was replaced by an 11-cm-long, 8-F sheath introducer (Boston Scientific), which allowed a loop fashioned from a 300-cm-long, 0.014-inch Cougar LS Nitinol guide wire (Meditronic, Minneapolis, Minnesota) to be pushed through the jugular access. This was used to snare the Terumo wire extremity within the IVC. The looped Cougar LS wire was pulled through the jugular venous access, and the floppy end of the Terumo wire was exteriorized (Fig 4a) . An Absolute Pro self-expanding vascular nitinol stent (8.0 mm in diameter and 40 mm in length; Abbott, Abbott Park, Illinois) on an 80-cm sheath was advanced over the floppy end of the Terumo wire and deployed within the right HV (Fig 4b) . A Charger balloon (7.0 mm in diameter and 40 mm in length; Boston Scientific) was used to fully expand the stent, after which stent patency was confirmed. During the procedure, the patient received low molecular weight heparin (3,000 IU), and, the following day, long-term anticoagulation was commenced for 1 year.
US evaluation 4 days later revealed a decrease in hepatic size (liver length at the midclavicular line of 14 cm). Doppler US showed turbulent hepatofugal flow within the stent (Fig 5) , with velocities reaching 130 cm/s. The portal vein maintained antegrade flow and normal velocity (50 cm/s) and the ascites had resolved. Throughout the following year, Doppler US follow-up did not show evidence of stent thrombosis, and there was clinical improvement (increase in weight of 7 kg and normal development, but a γ-glutamyl transpeptidase level of 140 U/L).
Endovascular recanalization of the HVs used to be done with balloon angioplasty, but it has been shown that stent implantation decreases the restenosis rate to 7% regardless of the obstruction etiology (1); stent placement is therefore now common practice.
Zhang et al (2), who studied the long-term effect of stent placement in Budd-Chiari syndrome, obtained an overall HV stent patency rate of 90.9%. The risk of stent occlusion was higher in HV stents (9.1%) than in IVC stents (3.3%).
Antegrade percutaneous approaches have been described, but present a potentially increased hemorrhagic risk as the liver capsule is punctured (2) . Even though it is probably safer, our approach cannot be widely used because direct drainage of the caudate lobe into the IVC is not always present. However, if this phenomenon is noted, we believe venography of this vessel should be performed to identify possible shunts. It is recognized that the caudate-lobe HV is engorged in 50% of patients with Budd-Chiari syndrome, and serves a pivotal role in liver drainage through multiple collateral vessels (3).
In summary, this report presents a case of a successful percutaneous endovascular recanalization, stent implantation, and balloon-aided stent expansion in the right HV in Budd-Chiari syndrome achieved through a collateral approach in a patient with a shunt between a patent caudate accessory HV and right HV.
